Navigation Links
ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
Date:6/11/2009

Panel of leading biopharma executives will discuss how Earned Value Management can improve control over clinical development costs, payments, and accruals and facilitate compliance with Sarbanes-Oxley at the DIA 45th Annual Meeting in San Diego.

Chicago, IL (PRWEB) June 11, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, Senior Director, Clinical Services, will chair a cross-functional panel of clinical finance and operations experts in discussing "Improving Accrual and Contract Management with Earned Value Management" at the DIA 45th Annual Meeting. Held at the San Diego Convention Center, June 21-25, 2009, the meeting will bring together the biggest names from industry, regulatory, and academia to discuss the issues affecting global drug discovery and development.

Given the unprecedented challenges facing biopharma companies, the ability to accurately measure the performance of clinical studies and better manage cost and schedule components is becoming even more critical. Earned Value Management (EVM), a widely accepted practice in many industries, has gained significant momentum in clinical development based on its ability to:

*Accurately calculate accruals based on when work is actually performed
*Quickly determine if studies are on budget by task, provider or resources
*Effectively track project performance and timelines to determine project health
*Facilitate compliance with Sarbanes-Oxley

Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the meeting, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis®. At ICOS, Lucas was responsible for establishing best practices in the outsourcing, management, drafting, and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment. Prior to ICOS, Lucas spent seven years with Genentech, where she was responsible for the negotiation, positioning, and pricing strategy for managed care contracts.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

# # #

Read the full story at http://www.prweb.com/releases/2009/06/prweb2522694.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
2. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
3. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
4. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
5. Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy
6. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
7. Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
8. Microtest Laboratories is an Industry Leader in ICH Stability Testing
9. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
10. Sugarcane Ethanol Industry Eager to Implement U.S. Renewable Fuel Standard
11. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):